[{"id":"49bd229e-a7a9-42f3-9559-2510a8eb6543","acronym":"LUN 17-139","url":"https://clinicaltrials.gov/study/NCT03786692","created_at":"2021-01-18T18:43:52.417Z","updated_at":"2024-07-02T16:35:19.761Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC","source_id_and_acronym":"NCT03786692 - LUN 17-139","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • EGFR exon 21 mutation • ROS1 rearrangement • EGFR exon 18 mutation","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • EGFR exon 21 mutation • ROS1 rearrangement • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-02-12"},{"id":"a207107c-5cf5-44dd-9047-a177e4c44953","acronym":"","url":"https://clinicaltrials.gov/study/NCT05104281","created_at":"2021-11-02T17:57:16.744Z","updated_at":"2024-07-02T16:35:52.031Z","phase":"Phase 3","brief_title":"Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05104281","lead_sponsor":"Qingdao Central Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 21 mutation • EGFR exon 18 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 21 mutation • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tagrisso (osimertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-03-29"},{"id":"4e59a070-93ee-46f8-9ecc-81e2ddf7222a","acronym":"BELIEF","url":"https://clinicaltrials.gov/study/NCT01562028","created_at":"2021-01-18T06:37:07.019Z","updated_at":"2024-07-02T16:36:04.901Z","phase":"Phase 2","brief_title":"BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)","source_id_and_acronym":"NCT01562028 - BELIEF","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • erlotinib"],"overall_status":"Completed","enrollment":" Enrollment 109","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 10/31/2018","study_completion_date":" 10/31/2018","last_update_posted":"2022-08-24"},{"id":"72174b71-caae-49d8-9560-477ac8bf3a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT01470716","created_at":"2021-01-18T06:07:39.841Z","updated_at":"2024-07-02T16:36:13.940Z","phase":"Phase 2","brief_title":"Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations","source_id_and_acronym":"NCT01470716","lead_sponsor":"National Cancer Center, Korea","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 21 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 21 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-04-06"},{"id":"fd5c192c-735b-49b3-81a7-a818b83a3a81","acronym":"secgolc004","url":"https://clinicaltrials.gov/study/NCT03720873","created_at":"2021-01-17T17:11:56.928Z","updated_at":"2024-07-02T16:37:05.799Z","phase":"Phase 2","brief_title":"EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC","source_id_and_acronym":"NCT03720873 - secgolc004","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 90","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 09/01/2022","study_completion_date":" 09/01/2022","last_update_posted":"2018-10-25"},{"id":"039e3c4d-74d4-42fb-bf4c-91ff4fe52199","acronym":"Geber","url":"https://clinicaltrials.gov/study/NCT03486496","created_at":"2021-01-18T17:10:24.278Z","updated_at":"2024-07-02T16:37:11.867Z","phase":"Phase 2","brief_title":"Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation","source_id_and_acronym":"NCT03486496 - Geber","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 06/05/2018","start_date":" 06/05/2018","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2018-04-03"},{"id":"3db967ee-1d50-4e41-a209-e60bcf159835","acronym":"","url":"https://clinicaltrials.gov/study/NCT01024413","created_at":"2021-01-17T17:40:51.874Z","updated_at":"2024-07-02T16:37:24.871Z","phase":"Phase 3","brief_title":"Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations","source_id_and_acronym":"NCT01024413","lead_sponsor":"Chinese Society of Lung Cancer","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR exon 21 mutation • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 21 mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib"],"overall_status":"Completed","enrollment":" Enrollment 256","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 06/01/2015","primary_completion_date":" 06/01/2015","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2017-03-01"}]